The full name of the trial is: "Conservative iron chelation as a...

The full name of the trial is: "Conservative iron chelation as a disease-modifying strategy in Parkinson's disease: a multicentric, parallel group, placebo-controlled, randomized clinical trial of deferiprone." To run from 2015 to 2020.

"17 national, European and international studies will be linked to the project. "

"Expected impact: The study results should prompt academic and industrial research on iron chelation and other disease-modifying treatments (which slow down disease progression) in Parkinson's disease and other neurodegenerative diseases."

So Fair Park 2 completion is planned for 2020. That could be interesting with PBT434 phase 1 due for completion in first half of 2019.

Conservative iron chelation is necessary with DFP because the strong metals attraction could be dangerous I guess. 

Prana have already started the multiple dose phase of the P1 according to the AGM poster. Recent work has identified that only labile(free) iron needs to be chelated, and with the hopefully safer PBT434, it will be interesting to see how high Prana takes the dose level. 

So far it looks to me like PBT434 will not have the dose limitations of DFP, but is strong enough to remove the required free iron. Remember DFP not only has a much stronger affinity to iron than PBT434, it has a stronger affinity to copper and zinc than PBT2. 

In Jan this year Prana indicated LT Toxicology to begin 2H 2018. Nothing in the AGM presentation to indicate that has started. That Jan presentation , called "Treatment of Neurological Disorders" also projected a P2 start 1H 20. On this AGM presentation the P2 start was not predicted, but they did say: "• Key work to support Phase 2 is ongoing". So Prana will probably be entering P2 as Fair Park 2 is completing, which could cause some interest. The new IND (FDA investigational new drug application) projected for 2H 19 could also create some interest.

All just my opinion. DYOR.